Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

Drugs

Volumn 53, Issue 2, 1997, Pages 299-336

  Haria, Malini ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANTACID AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; CIMETIDINE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MORBIDITY; MORTALITY; MYOPATHY; NONHUMAN; ORAL DRUG ADMINISTRATION; RASH; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031034647     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753020-00008     Document Type: Review

References (219)

1. Gotto AM, LaRosa JC, Hunninghake D, et al. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990; 81: 1721-33
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333-445
3. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990; 300: 667-72
4. Alberts AW. Effects of HMG CoA reductase inhibitors on cholesterol synthesis. Drug Invest 1990; 2 Suppl. 2: 9-17
5. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991; 42: 65-89
6. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1996; 51: 433-59
7. ER Squibb & Sons Limited. Pravastatin prescribing information. Middlesex, UK, 1994-5
8. Tsujita Y, Kuroda M, Shimada Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effects on various animal species. Biochim Biophys Acta 1986; 877: 50-60
9. Amorosa LF, Rozovski SJ, Ananthakrishnan R, et al. Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits. Jpn Heart J 1992; 33: 451-63
10. Koga T, Shimada Y, Kuroda M, et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-2-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 115-20
11. Reihnér E, Rudling M, Stählberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990; 323: 224-8
12. Ziegler K, Stünkel W. Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1992; 1139: 203-9
13. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993; 264: G36-44
14. Mosley ST, Kalinowski SS, Schafer BL, et al. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 1989; 30: 1411-20
15. De Vries ACJ, Cohen LH. Different effects of the hyperlipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim Biophys Acta 1993; 1167: 63-9
16. De Vries ACJ, Vermeer MA, Bloemendal H, et al. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthalmol Vis Sci 1993; 34: 377-84
17. Kalinowski SS, Tanaka RD, Mosley ST. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens. Exp Eye Res 1991; 53: 179-86
18. De Vries ACJ, Vermeer MA, Bredman JJ, et al. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not pravastatin. Exp Eye Res 1993; 56: 393-9
19. Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers. Atherosclerosis 1986; 61: 125-8
20. Pan HY, Willard DA, Funke PT, et al. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects. In Paoletti R, editor. Drugs affecting lipid metabolism, Berlin: Springer-Verlag, 1987: 255-9
21. Pan HY, DeVault AR, Wang-Iverson D, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-35
22. Pan HY, Triscari J, DeVault AR, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31: 665-70
23. Franceschini G, Cassinotti, M, Vecchio G, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994; 14: 1569-75
24. Slyper AH. Low-density lipoprotein density and atherosclerosis. JAMA 1994; 272: 305-8
25. Fieseler H-G, Armstrong VW, Wieland E, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation. Clin Chim Acta 1991; 204: 291-300
26. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993; 33: 574-80
27. Klausen IC, Gerdes LU, Meinertz H, et al. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest 1993; 23: 240-5
28. Umeda F, Watanabe J, Inoue K, et al. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus. Endocrinol Jpn 1992; 39: 45-50
29. Roheim PS. Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. Am J Cardiol 1986; 57: 3C-10C
30. Bard JM, Parra HJ, Douste-Blazy P, et al. Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin or cholestyramine therapy. J Drug Dev 1990; 3 Suppl. 1: 111-5
31. Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein sub-populations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993; 102: 107-19
32. Kazumi T, Yoshino G, Kasama T, et al. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apolipoproteins in patients with primary hypercholesterolaemia. Horm Metab Res 1986; 18: 654-5
33. Nakaya N, Goto Y. Effect of CS514 on hypercholesterolemic patients. In Paoletti R, editor. Drugs affecting lipid metabolism. Berlin: Springer-Verlag, 1987: 274-7
34. Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA 1987; 257: 3088-93
35. Saito Y, Goto Y, Nakaya N, et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects: a double blind test. Atherosclerosis 1988; 72: 205-11
36. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990; 227: 81-94
37. Yoshino G, Kazumi T, Iwai M, et al. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 1988; 71: 95-101
38. Franceschini G, Sirtori M, Vaccarino V, et al. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolaemia. J Lab Clin Med 1989; 114: 250-9
39. Goto Y, Yasugi T, Goto Y, et al. Clinical evaluation of CS-514 (pravastatin) on hyperlipidemia: double blind study with clinofibrate. Clin Evaluation 1988; 16: 211-49
40. Goto Y, Yamamoto A, Matsuzawa Y, et al. Clinical usefulness of pravastatin (CS-514) in the treatment of patients with hyperlipidemia: double-blind comparison with probucol. J Clin Exp Med 1988; 146: 927-55
41. Yoshino G, Matsushíta M, Iwaí M, et al. Two-year study on the effect of pravastatin (CS-514) on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients. Curr Ther Res 1989; 46: 144-52
42. Ikeda T, Ochi H, Ohtani I, et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobese, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia. Curr Ther Res 1992; 51: 593-9
43. Tawata M, Miwa I, Tsuchiya K, et al. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus. Arzneimittelforschung 1995; 45: 704-8
44. Yoshino G, Kuzumi T, Iwai M, et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75: 67-72
45. Kazumi T, Yoshino G, Ishida Y, et al. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 61-8
46. Watanabe J, Kobayashi K, Umeda F, et al. Apolipoprotein E polymorphism affects the response to pravastatin oil plasma apolipoproteins in diabetic patients. Diabetes Res Clin Pract 1993; 20: 21-7
47. Tail GW, Shepherd J. Hyperlipidaemia: its pathogenesis, clinical significance and treatment. Pharm J 1989; 242: 134-7
48. Kume N, Kita T, Mikami A, et al. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) and cholestyramine. Circulation 1989; 79: 1084-90
49. Kuroda M, Matsumuto A, Itakura H, et al. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol 1992; 59: 65-70
50. Shiomi M, Watanabe Y, Ito Y, et al. Suppressive effect of the combination treatment with pravastatin sodium and cholestyramine of the progression of atherosclerosis and xanthoma in mature WHHL rabbits. Presented at the 8th International Symposium on Atherosclerosis, 1988 Oct 9-13; Rome, Italy
51. Hayashi H, Naito C, Ito H, et al. The effect of pravastatin in relation to low density lipoprotein receptor activity. Curr Med Res Opin 1990; 12: 100-7
52. Khachadurian AK, Shimamura T, Rosovski SJ, et al. Pravastatin decreases serum lipids and vascular cholesterol in Watanabe heritable hyperlipidemic (WHHL) rabbits. Jpn Heart J 1991; 32: 675-85
53. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938-44
54. Shiomi M, Ito T, Watanabe Y, et al. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Atherosclerosis 1990; 83: 69-80
55. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 1995; 117: 225-36
56. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512-21
57. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24
58. Kool M, Lustermans F, Kragten H, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995; 48: 217-23
59. Corsini A, Raiteri M, Soma MR, et al. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 1992; 25: 399-400
60. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81
61. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996; 347: 305-7
62. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25
63. Corsini A, Raiteri M, Soma MR, et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21-8
64. Onaka H, Hirota Y, Kita Y, et al. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Jpn Circ J 1994; 58: 100-6
65. Yui Y, Kuwai C, Hosoda S, et al. Pravastatin (Mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate. Ann NY Acad Sci 1995; 748: 208-16
66. Sahni R, Maniet AR, Voci G, et al. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121: 1600-8
67. Weintraub WS, Boccuzzi SJ, Klein, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331-7
68. Lacoste LL, Lam JYT, Hung J, et al. Pravachol decreases cholesterol and platelet thrombus formation in coronary patients [abstract no. 73]. Can J Cardiol 1993; 9 Suppl. E: 83E
69. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7
70. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolaemic coronary patients [abstract no. 1045-19]. J Am Coll Cardiol 1996; 27 Suppl. A: 413A
71. Mori Y, Noda A, Sakaguchi T, et al. Effect of pravastatin on coagulation and fibrinolytic systems in patients with hypercholesterolemia [in Japanese]. J Kessen Shiketsu 1991; 2: 501-4
72. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829-34
73. Barrow SK, Stratton PD, Benjamin N, et al. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease. Br J Clin Pharmac 1991; 32: 127-9
74. Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 1990; 85: 249-56
75. Tsuda Y, Satoh K, Takahashi T, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993; 12: 360-4
76. Tsuda Y, Satoh K, Kitadai M, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33
77. Branchi A, Rovellini A, Sommariva D, et al. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3
78. Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993; 42: 1146-52
79. Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Pharmacol 1991; 32: 417-22
80. Ito H. The effects of CS-514 (pravastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipids and steroid hormones in the hypercholesterolemic elderly. J Clin Ther Med 1988; 4: 395-407
81. Dobs AS, Martin KM, Nazelrod B, et al. Is reduced vitamin D synthesis a complication of treatment with HMG-CoA reductase inhibitors? [abstract]. Arteriosclerosis 1988; 8: 635A
82. Hoogerbrugge-vd Linden N, de Rooy FWM, Jansen H, et al. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 1990; 31: 348-50
83. Horiuchi I, Ohya T, Tazuma S, et al. Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia. Metabolism 1991; 40: 226-30
84. Kajiyama G, Horiuchi I, Takata K, et al. Effects of CS-514 on biliary lipid metabolism in patients with hyperlipidemia. J Clin Ther Med 1988; 4: 191-200
85. Tazuma S, Ohya T, Teramen K, et al. Effects of long-term treatment with low-dose pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on biliary lipid metastability in patients with hypercholesterolemia [abstract no. 1005]. Hepatology 1993; 18: 308A.
86. Bär PR, Bredman JJ, Koot RW. Simvastatin and lovastatin, but not pravastatin, induce myopathy in young rats [abstract no. 131]. Eur J Clin Invest 1993; 23 Suppl. 1: A24
87. Fukami M, Maeda N, Fukushige J, et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med 1993; 193: 263-73
88. Reijneveld JC, Koot RW, Bredman JJ, et al. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Paediatr Res 1996; 39: 1028-35
89. Smith PF, Eydelloth RS, Grossman SJ, et al. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. Eur Heart J 1992; 13 Suppl. B: 2-6
90. Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231-6
91. Kamei Y, Shirakawa S, Ishizuka Y, et al. Effect of pravastatin on human sleep. Jpn J Psychiatry Neurol 1993; 47: 643-6
92. Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426-32
93. Vgontzas AN, Kales A, Bixler EO, et al. Effecfs of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991; 50: 730-7
94. Cutler N, Sramck J, Veroff A, et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmac 1995; 39: 333-36
95. Eckernäs S-A, Roos B-E, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmac 1993; 35: 284-9
96. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994; 34: 989-96
97. Partinen M, Pihl S, Strandberg T, et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol 1994; 73: 876-80
98. Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int 1995; 48 Suppl. 52: S112-5
99. Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995; 116: 1894-8
100. Ichihara K, Satoh K, Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J Cardiovas Pharmacol 1993; 22: 852-6
101. Van Boven AJ, Jukema JW, Zwinderman AH, et al. Pravastatin reduces transient myocardial ischemia in patients with angina pectoris and significant CAD [abstract no. 751-5]. J Am Coll Cardiol 1996; 27 Suppl. A: 165A
102. Van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503-5
103. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-7
104. Singhvi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239-43
105. Sasahara K, Kawabata K. Phase 1 study of CS-514, an inhibitor of HMG-CoA reductase II: pharmacokinetics of CS-514 in healthy volunteers. J Clin Ther Med 1988; 4: 45-65
106. Pentikainen PJ, Saraheimo M, Schwartz JL, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32: 136-40
107. Koga T, Kawabata K, Arai K, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and simvastatin. Bull Mol Biol Med 1995; 20: 103-5
108. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291-4
109. Triscari J, Pan H, DeVault A, et al. Comparative bioavailability of pravastatin following morning and evening dosing [abstract no. PIII-19]. Clin Pharmacol Ther 1991; 49: 178
110. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia II. Once-daily versus twice-daily dosing. Atherosclerosis 1990; 85: 219-27
111. Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151-60
112. Pan H, Fleiss P, Moore L, et al. Excretion of pravastatin, an HMG-CoA reductase inhibitor, in breast milk of lactating women. J Clin Pharmacol 1988; 28: 942
113. Botti RE, Triscari J, Pan HY, et al. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991; 14: 256-61
114. Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263-5
115. Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 1085-90
116. Saheki A, Terasaki T, Taillai I, et al. In vivo and in vitro blood brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994; 11: 305-311
117. Squibb & Sons, Inc. Pravastatin prescribing information. New Jersey, USA, 1995
118. Halstenson CE, Triscari J, Devault A, et al. Single dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992; 32: 124-32
119. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40 Suppl. 1: S15-8
120. Pan HY, Waclawski AP, Hinke PT, et al. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993; 27: 1029-33
121. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-69
122. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916-24
123. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89
124. McGovern MH, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993; 14: 57-64
125. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
126. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
127. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
128. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309-14
129. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76: 113C-7C
130. WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485-91
131. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
132. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1334-5
133. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-7
134. Pfeffer MA, Sacks FM, Moyé LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995; 76: 98C-106C
135. Sacks FM, Rouleau J-L, Move LA, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995; 75: 621-3
136. Mellies MJ. Ongoing and planned clinical trials for atherosclerosis prevention and regression. Curr Opin Invest Drugs 1993; 2: 529-39
137. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
138. LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474-9
139. Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 107C-12C
140. Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) project and the Cholesterol Treatment Trialists (CTT) collaboration. Am J Cardiol 1995; 76: 122C-6C
141. PPP Project Investigators. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project - a combined analysis of three large-scale randomized trials: Long-Tenn Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995; 76: 899-905
142. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419-25
143. Salonen R, Nyyssönen K, Porkkala E, et al. Kunpio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64
144. Pitt B, Ellis SG, Mancini GBJ, et al. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31-5
145. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reductions in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9
146. Byington RP, Furberg CD, Crouse JR, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 76: 54-9C
147. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995; 75: 455-9
148. Barth JD, Zonjee MMB, REGRESS Research Group. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. Can J Cardiol 1992; 8: 925-32
149. De Groot E, Jukema JW, van Boven AJ, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol 1995; 76: 40-6C
150. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Stalin Study (REGRESS). Circulation 1995; 91: 2528-40
151. Jukema JW, van Boven AJ, Bal ET, et al. During lipid-lowering therapy or placebo administration progression and regression of coronary lesions occur within the same patient [abstract no. 1217]. Eur Heart J 1994; 15 Suppl.: 223
152. Jukema JW, van Boven AJ, Reiber JHC, et al. Progression and regression of coronary atherosclerosis occur within the same patient during placebo treatment and during lipid-lowering therapy with pravastatin [abstract no. 769-2]. Program and abstracts of original contributions from the 44th Annual Scientific Session American College of Cardiology: 1995 March 19-22: New Orleans, Louisiana, USA; J Am Coll Cardiol (Feb) 1995; 281A
153. Jukema JW, van Boven AJ, Reiber JHC, et al. Reduction of the beneficial effect of lipid-lowering therapy by pravastatin on coronary atherosclerosis in smoking patients [abstract no. 1584]. Abstracts from the XVIIth Congress of the European Society of Cardiology: 1995 August 20-24: Amsterdam, The Netherlands; Eur Heart J 1995; 16 Suppl.: 273
154. De Groot E, Jukema JW, Zwinderman AH, et al. Correlations in pravastatin treatment effect between carotid and femoral intima-media thickness, and coronary artery stenosis [abstract 988-22]. J Am Coll Cardiol 1996; 27 Suppl. A: 273A
155. Furherg CD, Pitt B, Byinglon RP, et al. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995; 76: 60-3C
156. Sacks FM, Gibson CM, Rosner B, et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol 1995; 76: 78C-85C
157. PHYLLIS Project Group. Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. J Hypertens 1993; 11 Suppl. 5: S314-5
158. Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safely of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci 1993; 29: 272-7
159. Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med 1995; 155: 1900-6
160. Rubenfire M, Maciejko JJ, Blevins RD, et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991; 151: 2234-40
161. Hunninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia I. A dose-response study. Atherosclerosis 1990; 85: 81-9
162. Belleridge DJ, Bhatnager B, Bing RF, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992; 304: 1335-8
163. Wiklund O, Angelin B, Fager G, et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990; 228: 241-7
164. Arntz HR, Bönner G, Kikis D, et al. Efficacy of pravastatin and bezafibrate in primary hypercholesterolaemia [in German]. Dtsch Med Wochenschr 1991; 116: 7-12
165. Crepaldi G, Baggio G, Area M, et al. Piavastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I. Arch Intern Med 1991; 151: 146-52
166. Malacco E, Magin A, Scandiani L, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolaemia. Drug Invest 1994; 7: 331-9
167. Jacolot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolaemia. Am J Cardiol 1995; 76: 54A-6A
168. Kawakami Y, Tagami S, Hasegawa A, et al. Clinical efficacy of fluvastatin (XU62-320) in hyperlipidemia - a comparative study with pravastatin in a double-blind comparative method [in Japanese]. Rinsho Iyaku 1995; 11: 1679-1726
169. Lovastatin Pravastatin Study Group. A multicenter omparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-5
170. McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992; 14: 276-91
171. Weir MR, Berger ML, Weeks ML, et al. Comparison of the effects on qualily of life and of the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol 1996; 77: 475-9
172. European Study Group. Efficacy and tolerability of simvastatin and
173. Lambrecht LJ, Malini PL, European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol 1993; 48: 541-54
174. Steinhagen-Thiessen E. Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 1994; 85: 244-54
175. Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14
176. Illingworth DR, Erkelens WD, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554-5
177. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and in combination in patients with hypercholesterolemia. Arch Intern Med 1993; 153: 1321-9
178. Jacob BG, Möhrle W, Richter WO, et al. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol 1992; 42: 353-8
179. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and ω-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia Arterioscler Thromb 1993; 13: 1755-62
180. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-20
181. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-45
182. O'Keefe JH, Harris WS, Nelson J, et al. Effects of pravastatin with macin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995; 76: 480-4
183. Davidson MH, Gwynne JT, Khachadurian AK, et al. Combination of pravastatin and probucol in the treatment of primary hypercholesterolemia. Coron Artery Dis 1991; 2: 1061-8
184. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framington study. JAMA 1987;257:2176-80
185. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518-31
186. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause morlality in persons older than 70 years. JAMA 1994; 272: 1335-40
187. Bo M, Pernigotti L, Poli L, et al. 1991. One-year experience in the treatment of elderly hypercholesterolemic patients with pravastatin. Curr Ther Res 1991; 50: 151-8
188. Glasser SP, DiBianco R, Effron BA, et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low - density lipoprotein cholesterol > 160 mg/dl. Am J Cardiol 1996; 77: 83-5
189. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994; 96: 509-15
190. Mellies MJ, DeVault AR, Kassler-Taub K, et al. Pravastatin experience in elderly and non-elderly patients. Atherosclerosis 1993; 101: 97-110
191. Chan P, Lee C-B, Lin T-S, et al. The effectiveness and safely of low dose pravastatin in elderly hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995: 8: 1099-104
192. Bierman EL. Atherogenesis in diabetes: George Lyman Duff memorial lecture. Arterioscler Thromb 1992; 12: 647-56
193. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-69
194. Anonymous. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 Suppl. 2: 106-12
195. Behounek BD, McGovern ME, Kassler KB, et al. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Clin Cardiol 1994; 17: 558-62
196. Deerochanawong C, Serirat S. Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus. J Med Assoc Thai 1995; 78: 113-7
197. Krempf M, Berthezene F, Wemeau JL, et al. Efficacite et tolerance de la pravastatine chez des patients presentant une hypercholesterolemie associee a un diabete de type II [abstract]. Diabete Metab 1993; 19: 44
198. Raskin P, Ganda OP, Schwartz S, et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med 1995; 99: 362-9
199. Sheu WHH, Shieh SM, Shen DDC, et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994; 127: 331-6
200. Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37: 847-53
201. Spitalewitz S, Porush JG, Cattran D, et al. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993; 22: 143-50
202. Tokoo M, Oguchi H, Terashima M, et al. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome. Jpn J Nephrol 1992; 34: 397-403
203. Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991; 39 Suppl. 31: S35-40
204. Mori Y, Tsuruoka A. Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellilus [in Japanese]. J Jpn Diabetes Soc 1992; 35: 265-6
205. Shoji T, Nishizawa Y, Toyokawa A, et al. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 1991; 59: 664-5
206. Alamo C, Aranda JL, Sánchez R, et al. Treatment of proteinuria-related hyperlipidemia with pravastatin [abstract]. Kidney Int 1994; 46: 562
207. Motellón JL, Sánchez-Tomero A, Gruss E, et al. Treatment with pravastatin of hypercholesterolaemia in nephrological patients: effects on proteinuria and progression of renal failure [abstract]. Nephrol Dial Transplant 1994; 9: 962
208. Hattori M, Ito K, Kawaguchi H, et al. Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrolic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 1993; 7: 196-8
209. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94-9
210. Castelao AM, Grinyó JM, Castiñeiras MJ, et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation undercyclosporine and prednisone. Transplant Proc 1995; 27: 2217-20
211. Lye WC, Hughes K, Leong SO, et al. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 1995; 27: 977-8
212. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469-74
213. Schouten JA, Rila H, Gevers Leuven J, et al. Tandem study: efficacy and safety of pravastatin in hypercholesterolemic patients with hypertension [abstract no. 470]. Atherosclerosis 1995; 115 Suppl.: S125
214. Waeber B, Greminger P, Riesen W, et al. Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. Blood Press 1995; 4: 358-62
215. Fogari R, Marasi G, Zoppi A, et al. Effects of pravastatin given every other day in dyslipidemic hypertensives treated with different antihypertensive drugs [abstract no. A62]. Am J Hypertens 1994; 7 (4 Pt 2): 48A
216. Tsukiyama H, Otsuka K. Effects of pravastatin in dyslipidaemic patients with and without hypertension. J Hypertens 1993; 11 Suppl. 5: S346-7
217. O'Callaghan CJ, Conway EL, Lam W, et al. Effects of pravastatin on the lipid profile of hypertensive patients receiving captopril [abstract no. 1558]. Am J Hypertens 1993; 6 (5 Pt 2): 109A
218. Muramatsu J, Kobayashi A, Ikeda Y, et al. Change in cardiac function after long-term treatment of hyperlipidemia by a HMG-CoA reductase inhibitor (pravastatin) in patients with hypertension and ischemic heart disease [abstract no. P979]. Jpn Circ J 1993; 57: 744
219. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7